Citation Impact
50 standout
Citing Papers
CAR T therapies in multiple myeloma: unleashing the future
2024 Standout
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients
2024 Standout
Works of Devender Dhanda being referenced
Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).
2023
Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121)
2021
Author Peers
| Author | Hematology | Oncology | Molecular Biology | PRM | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Devender Dhanda | 70 | 97 | 70 | 103 | 33 | 264 | |
| Usree Kirtania | 29 | 2 | 10 | 365 | |||
| Ángel Álvarez‐Larena | 2 | 517 | 581 | 13 | 135 | 2.7k | |
| Robert C. Spindel | 13 | 72 | 1.4k | ||||
| Wen-Hua Hsieh | 13 | 7 | 38 | 237 | 14 | 1.4k | |
| Flavio Cermola | 8 | 103 | 29 | 70 | 731 |
All Works
Login with ORCID to disown or claim papers
Loading papers...